Popular Articles From: Genesis Energy, L.P. Announces Public Offering of Common Units to Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014

Genesis Energy, L.P. (NYSE: GEL) today announced the commencement of a registered underwritten public offering of 4,000,000 common units representing limited partner interests.
Sign-up for Genesis Energy, L.P. Announces Public Offering of Common Units investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1130923&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for GBST Syn~ Goes Live at Raymond James investment picks
Garrison Capital Inc. a business development company (the “Company”) (NASDAQ: GARS), today announced that certain of its stockholders (the “Selling Stockholders”), affiliates of funds managed or advised by Garrison Investment Group LP, have priced an underwritten, public offering of 2,000,000 shares of the Company’s common stock at a public offering price of $14.50 per share.
Sign-up for Garrison Capital Inc. Prices Public Offering of 2,000,000 Shares of Common Stock investment picks
Garrison Capital Inc., a business development company (the “Company”) (NASDAQ:GARS), today announced certain preliminary estimates for the quarter ended June 30, 2014.
Sign-up for Garrison Capital Inc. Announces Certain Preliminary Estimates for the Second Quarter Ended June 30, 2014 investment picks
Gap Inc. (NYSE: GPS) today announced plans to enter India through franchise-operated Gap brand stores in 2015.
Sign-up for Gap Inc. Announces Plans to Extend International Presence to India through Franchise Agreement investment picks
Kimco Realty Corp.
Sign-up for Fresh Thyme Farmers Market to Open at Kimco’s North West Square in Columbus, Ohio investment picks
e-Therapeutics plc (AIM:ETX), the drug discovery and development company, today announces its half year results for the six months ended 31 July 2014.
Sign-up for Four Clinical Trials in Progress; New Drug Candidates in Laboratory Testing investment picks
http://media.marketwire.com/attachments/200903/514817_FortinetNew.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1133529&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for Fortinet Unveils New Network Security Expert Certification Program investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Fortegra Financial Corporation (“Fortegra”) (NYSE: FRF) concerning the acquisition by Tiptree Financial Inc. (“Tiptree”). Under the terms of the agreement, valued at approximately $218 million, Fortegra shareholders will only receive $10 in cash per share owned.
Sign-up for FORTEGRA FINANCIAL SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Tiptree Financial investment picks
Accuvant , the authoritative source for enterprise information security, today announced that former Coca-Cola chief information security officer (CISO) Renee Guttmann has joined the company as a vice president in the Accuvant Office of the CISO.
Sign-up for Former Fortune 50 CISO Renee Guttmann Joins Accuvant investment picks
By Sital S.
Sign-up for Five questions with Carlyle's chief economist investment picks
The challenges that face Booz Allen Hamilton’s (NYSE: BAH) clients are as diverse as their organizations.
Sign-up for Fiscal Year 2014: The Power of Booz Allen Hamilton’s Innovation Stands Out in “Reaching Forward: Inventing the Future” investment picks
The majority of consumers want person-to-person (P2P) payments from their primary financial institution , and FIS ™ (NYSE: FIS), the world’s largest provider of banking and payments technology solutions and a global leader in consulting and outsourcing solutions, is leading the way in making it a reality.
Sign-up for FIS Brings Instant P2P Payments Capabilities to EverBank investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMB r I sentan and T adalafil in patients with pulmonary arterial hypertens ION ), which was conducted in collaboration with GlaxoSmithKline (GSK). In AMBITION, first-line treatment of pulmonary arterial hypertension (PAH) with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50 percent compared to the pooled ambrisentan and tadalafil monotherapy arm (hazard ratio = 0.502; 95 percent CI: 0.348, 0.724; p=0.0002). The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint (p<0.01). Rates of serious adverse events and events leading to discontinuation were similar across treatment arms.
Sign-up for First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study investment picks
First Trust/Aberdeen Global Opportunity Income Fund (the “Fund”) (NYSE: FAM) has declared the Fund’s regularly scheduled monthly common share distribution in the amount of $0.11 per share payable on August 15, 2014, to shareholders of record as of August 5, 2014.
Sign-up for First Trust/Aberdeen Global Opportunity Income Fund Declares its Monthly Common Share Distribution of $0.11 Per Share for August investment picks
Announces Agreement to Purchase Nine Branch Banking Offices WASHINGTON, N.C. , Sept.
Sign-up for First South Bank Strengthens Commitment to Eastern North Carolina investment picks
Rancho Mirage, CA, Aug.
Sign-up for Fertility Financing Now Offered Through New Life Partnership With LightStream investment picks
- Assembly Row Orange Line T Station Now Open - J.Crew Factory, LOFT Outlet and Banana Republic Factory Store Join 25 Key Tenants Open in Phase 1 - Partners HealthCare Commences Office Campus for over 4500 Employees ROCKVILLE, Md.
Sign-up for Federal Realty's Assembly Row Achieves Key Opening Milestones investment picks
ARLINGTON, Va., July 21, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR & Co. Announces Self Tender Offer to Purchase up to One Million Shares investment picks
Sign-up for FBR & Co. Announces Final Results of Self-Tender Offer investment picks
F5 Networks, Inc. (NASDAQ: FFIV ) announced today that on August 1, 2014, the company issued a total of 23,000 restricted stock units (“RSUs”) to 11 employees who joined F5 in connection with the company’s acquisition of Defense.Net, Inc., a provider of cloud-based security services for protecting data centers and Internet applications from distributed denial-of-service (DDoS) attacks.
Sign-up for F5 Networks Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring the BRAF V600 mutation.
Sign-up for Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma investment picks
EXCO Resources, Inc. (NYSE:XCO) (“EXCO”) today announced that, effective September 19, 2014, Richard A.
Sign-up for EXCO Resources, Inc. Announces Senior Executive Changes investment picks
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of EVOQ Properties, Inc. (“EVOQ” or the “Company”) (OTC: EVOQ) relating to the sale of the Company to an entity formed by affiliates of Atlas Capital Investors III, LLC, Square Mile Capital Management, LLC and USAA Real Estate Company (the “Investor Group”). On August 18, 2014, EVOQ announced the signing of a definitive merger agreement pursuant to which the Investor Group will acquire EVOQ in a merger valued at roughly $357.4 million.
Sign-up for EVOQ INVESTOR ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of EVOQ Properties, Inc. - EVOQ investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Zydelig ® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
Sign-up for European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma investment picks
Essex Rental Corp.
Sign-up for Essex Rental Corp. Reports 2014 Second Quarter Results investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Wednesday, August 13, 2014 at 8:00 a.m. ET to report second quarter 2014 financial results and provide a corporate update.
Sign-up for Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014 investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.


Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Popular Articles From: Genesis Energy, L.P. Announces Public Offering of Common Units to Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices